Biotech
New AI-Powered Ultrasound Software Revolutionizes Cardiovascular Diagnosis in Primary Care
AI-powered ultrasound software enhances real-time guidance, ensuring optimal images and reducing errors, enabling more accurate diagnoses without complex machines. Dr. Ana Segura highlighted its transformative impact in primary care, particularly for cardiovascular disease diagnoses. Accessible in clinics, emergency rooms, and home visits, it reduces specialist referrals and enables faster treatments.
New ultrasound software powered by artificial intelligence (AI) aims to transform the way heart disease is diagnosed in primary care. This innovative wireless ultrasound system, presented at the Semergen Congress, is designed to capture cardiac images with great precision. The ultrasound software facilitates rapid and reliable diagnoses, which represents a crucial advance in the early detection of cardiovascular pathologies.
Furthermore, thanks to its AI-based technology, the ultrasound software is able to guide healthcare professionals in real time to optimize the use of the ultrasound probe. An integrated quality meter ensures that the images obtained are optimal in each examination. This reduces the margin of error and helps doctors to obtain the best results without depending on complex hospital machines.
During the seminar Role of clinical ultrasound in acute abdominal pain, Dr. Ana Segura Grau, member of the Semergen Ultrasound Working Group, highlighted the importance of this ultrasound software in the primary care setting. In her words, “the capacity of this system to guide in real time and ensure optimal images represents a significant change in daily practice, allowing faster and more accurate diagnoses of cardiovascular diseases.”
The ultrasound software offers a level of accessibility that was previously unavailable to family doctors
It allows for use in health centres, emergency rooms and home visits. This ease of use helps reduce the need to refer patients to specialists or hospitals, which means an improvement in the management of healthcare resources. Dr. Inés Salcedo, also a participant in the congress, commented that “this technology allows for earlier diagnoses and more effective treatments, especially for patients who cannot wait long periods for more complex tests.”
Dr. Ana Segura: “The ability of this system to guide in real time and ensure optimal images represents a significant change in daily practice, allowing faster and more accurate diagnoses of cardiovascular diseases”
The ultrasound software delivers high-quality images and can also automatically calculate left ventricular ejection fraction, one of the main indicators of cardiac function. In addition, it automatically saves the best image loop once the quality threshold has been reached. This reduces the margin of error in data acquisition, giving professionals greater confidence when interpreting the results.
This new ultrasound software, backed by artificial intelligence, is also useful for doctors with less experience in ultrasound. It guides them through each step of the process and ensures that the images obtained are suitable for an accurate diagnosis.
The Semergen Congress has highlighted the importance of equipping primary care physicians with advanced technological tools. These are capable of improving the diagnosis and monitoring of patients quickly and accurately. In addition, they respond to the growing demand for medical services due to the ageing of the population.
__
(Featured image by Alexander Sinn via Unsplash)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in iSanidad. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us
-
Cannabis2 weeks ago
Teen Cannabis Use Declines in the U.S.: How Has Legalization Impacted Youth?
-
Markets4 days ago
Gold and S&P 500 Hit Historic Highs in a Race for the Century’s Top Spot
-
Markets1 week ago
Why New York and London Coffee Markets Closed Lower This Past Week
-
Biotech2 days ago
Córdoba Biotech Started the Process to Select 20 New Startups